Affymetrix signs definitive contract to acquire eBioscience Affymetrix, Inc., today announced that it offers signed a definitive agreement to obtain eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay reagents for oncology and immunology research and diagnostics. Under the terms of the agreement, Affymetrix will acquire eBioscience for $330 million in cash at the mercy of certain customary adjustments. The transaction is subject to customary closing circumstances and is expected to close late in the fourth one fourth of 2011.Plasma creatinine was measured at baseline; at 2, 6, and 12 weeks; and then every 12 weeks. Blood circulation pressure was measured and the ratio of urinary albumin to creatinine was decided at baseline and every 26 weeks. Plasma lipid and alanine aminotransferase levels were measured and a health-status questionnaire was administered at baseline, at 12 and 52 weeks, and then annually.9 Main and Secondary Outcomes The principal 3-year outcome was the glycated hemoglobin level.